Caregen Co., Ltd. (CEO Yongji Jeong), a peptide-specialized bio company, announced on the 23rd that it has signed an exclusive supply contract in China for three types of its peptide-based health functional foods with Yishijin Pharmaceutical Group, a major Chinese traditional medicine company in Hubei Province.
This contract is worth approximately KRW 557 billion (USD 389.5 million) over five years, and is a large-scale partnership that will allow Caregen's health functional foods to fully enter the Chinese market.
Lishijin Pharmaceutical Group is a comprehensive traditional Chinese medicine company located in Qichun, Hubei Province, named after Li Shijin, the author of the Ming Dynasty medical book "Compendium of Materia Medica." Its main products are herbal medicine preparations and health foods, and in line with the Chinese government's policy of modernizing traditional Chinese medicine, it is concentrating on developing new drugs that combine biotechnology and traditional medicine.
As the market for metabolic diseases such as obesity and diabetes and sports nutrition rapidly grows in China, demand for peptide-based health functional foods is increasing. Caregen's Coglutide, Myoki, and Progesterone products are proven to be effective in weight control, promoting muscle growth, and improving insulin resistance.
Leesijin Pharmaceutical Group plans to begin sales in China in December 2025 and prioritize cross-border sales worth approximately KRW 82 billion in 2026-2027, prior to product registration. Upon signing the contract, a down payment of USD 2 million was made, establishing a minimum guaranteed amount, securing a stable revenue base.
The Yishijin Pharmaceutical Group operates a chain of directly managed pharmacies and flagship stores in major online malls in China, and plans to quickly supply Caregen products to the market through a nationwide offline distribution network.
Caregen CEO Jeong Yong-ji said, “Through this contract, we are actively entering the Chinese market and are also expanding our production capacity in preparation for global market expansion,” adding, “We plan to expand our supply chain to major Asian countries in the future.”
With this contract, Caregen plans to expand its peptide health functional food business in China and explore collaborations with multinational pharmaceutical companies by participating in a major European pharmaceutical event in November.
- See more related articles
You must be logged in to post a comment.